Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan
Wataru Sasaki(Hiroshima University), Mariko Sugawara‐Mikami(Miwa Internal Medicine Clinic), Machiko Kamura(Saga University), Ken Igawa(Dokkyo Medical University), Toshiya Takahashi(Tohoku University), Ryo� Saito(Hiroshima University), Kazumitsu Sugiura(Fujita Health University), Akio Tanaka(Hiroshima University), Sei‐ichiro Motegi(Unknown), Ryoichi Kamide(Ono Clinic), Daisuke Watanabe(BOKU University), Toshifumi Nomura(Hokkaido University), Maki Ozawa(Tohoku University), Masakazu Takahashi(Yamaguchi University), Masako Minami‐Hori(Asahikawa City Hospital), Yoko Kataoka(Osaka Prefectural Medical Center), Noriko Kubota(University of Tsukuba), Kazunari Sugita(Saga University), Hirofumi Kamada(Iwate Medical University), Akihiko Uchiyama(Gunma University), Takashi Yamakita(Fujita Health University), Hiroo Amano, Kenta Suzuki(Niigata University), Tetsuharu Ikegami(Dokkyo Medical University)
Cited by 8
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Role of neutrophils in induction of acute inflammation in T‐cell‐mediated immune dermatosis, psoriasis: A neutrophil‐associated inflammation‐boosting loop
|Experimental Dermatology|2000|149
Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)
|British Journal of Dermatology|2016|125
Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double‐Blind, Randomized, Parallel‐Group Trial
|Arthritis & Rheumatology|2016|119
Psoriasis and Antimicrobial Peptides
|International Journal of Molecular Sciences|2020|114